Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Hutchmed China Ltd.
Industry Sector: HealthTechnology
CEO: Wei Guo Su, PhD
Number Of Employees: 1,811
Enterprise Value: $1,803,762,226
PE Ratio: 64.12
Exchange/Ticker 1: LSE:HCM
Exchange/Ticker 2: NASDAQ:HCM
Latest Market Cap: $2,512,725,344
BioCentury | Jan 7, 2025
Deals
Irish sale from Wuxi Biologics, Roche looks to Innovent for ADC
BioCentury’s Deals Report: Wuxi Biologics, Hutchmed in asset sales and more
BioCentury | Nov 27, 2024
Product Development
The late-stage pancreatic cancer landscape: innovation level modest
PDAC candidates mostly small molecules against old targets, as a pair of radiopharmaceuticals competes in pancreatic neuroendocrine setting
BioCentury | May 17, 2024
Management Tracks
Hutchmed names new chairman as Simon To retires
Plus: Immunome promotes Max Rosett to CFO, and Mark de Jong becomes CTO at Full-Life
BioCentury | Apr 30, 2024
Data Byte
EMA’s CHMP recommends Takeda VEGF therapy, Idorsia hypertension drug
April opinions also include earlier-line use of J&J’s Rybrevant and BMS’s Opdivo
BioCentury | Mar 22, 2024
Politics, Policy & Law
Congress broadening anti-China life sciences focus
Senators investigating biotech, calling for export restrictions
BioCentury | Feb 6, 2024
Deals
Deals roundup: Novo boosts obesity manufacturing with Catalent buy
BioCentury’s weekly roundup of biopharma deals, Jan. 30- Feb. 5
BioCentury | Dec 7, 2023
Data Byte
FDA approves six NMEs in November
The four cancer therapies among the approvals included the first AKT inhibitor and the first desmoid tumor therapy
BioCentury | Nov 9, 2023
Regulation
Nov. 8 Quick Takes: FDA approves Lilly’s tirzepatide for weight loss
Plus: Takeda’s fruquintinib approved for colorectal cancer, and updates from Forward, Ascidian, Xencor, UltraDx and more
BioCentury | Oct 31, 2023
Data Byte
Nine PDUFA dates on FDA’s November roster
Decisions include the first vaccine for Chikungunya and three new cancer therapies
BioCentury | May 26, 2023
Finance
May 25 Quick Takes: VarmX is latest biotech to extend series B
Plus: Apellis/Sobi candidate misses in ALS and updates from Annexon, Pfizer and more
Items per page:
1 - 10 of 45